Breckenridge Pharmaceutical, Inc. recalls
12 recall notices naming Breckenridge Pharmaceutical, Inc. since January 2025, in United States. The most recent was published 17 Jun 2026.
12recalls on record
Latest recalls (12)
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- FDABreckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
- FDABreckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- FDABreckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.